New combo therapy aims to shrink tough bladder cancers before surgery
NCT ID NCT05137262
Summary
This study is testing if adding a drug called durvalumab (an immunotherapy) to standard chemotherapy works better than chemotherapy alone for bladder cancer that has spread to nearby lymph nodes. The goal is to shrink the cancer more effectively before surgery. Patients will be randomly assigned to receive either the standard chemo or the chemo plus durvalumab, and the durvalumab may be continued as a maintenance treatment for up to a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University
Bloomington, Indiana, 47405, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.